Rising Use of Unregulated Peptide BPC-157 Highlights Data Gaps and Safety Concerns

BPC-157, a gray-market peptide touted for injury recovery, is seeing rapid growth in use despite minimal clinical evidence or regulatory approval. Limited and imperfect data from health records demonstrate increasing usage but raise substantial questions about safety, efficacy, and patient disclosure.

BPC-157, an unapproved peptide originally found in gastric juice, is gaining widespread attention as a purported injury recovery aid. Studies mostly in animals suggest it may help tissue repair by promoting new blood vessel growth and cell regeneration. However, despite rising popularity, BPC-157 lacks regulatory approval and robust clinical evidence in humans, with only one clinical study identified in a 2025 systematic review.

Interest in BPC-157 has surged dramatically, with millions of views on social media platforms and a 1,600 percent increase in web searches in the United States over five years. Researchers have struggled to gather reliable data due to the peptide’s gray-market status and lack of standardized clinical reporting.

A recent preprint study analyzed anonymized electronic health records using an AI language model to identify mentions of BPC-157, revealing a notable increase in documented patient use—from 54 patients in early 2022 to over 1,000 in early 2026. About one-third of these patients used BPC-157 alone, while others combined it with substances like testosterone and TB-500. Most users were reported to take it orally or via injections.

Despite these insights, the data remain limited and suggest demographic disparities in disclosure rates, with Caucasian patients more likely to report usage than African American patients. This gap may reflect differing comfort levels discussing gray-market substance use with healthcare providers. The study also revealed that most adverse effects were self-reported and minor, but objective assessments and comprehensive safety data are lacking.

Researchers emphasize that the available information cannot reliably determine BPC-157’s efficacy or safety. The unregulated nature of the product means some users might receive substances other than BPC-157, and placebo effects cannot be ruled out. Moreover, patients often delay discussing use with physicians, complicating clinical understanding.

Experts urge healthcare systems to facilitate better documentation of gray-market substance use to improve data collection. Ultimately, robust clinical trials and prospective studies are crucial to clarify the medical value and risks of BPC-157 and similar peptides. Until then, clinicians face challenges in advising patients using these substances outside formal regulatory frameworks.

The growing use of BPC-157 underscores a larger trend in unapproved peptides, highlighting the urgent need for more rigorous research despite financial and regulatory hurdles. Presently, incomplete and anecdotal data remain the primary source of information for patients, physicians, and regulators confronting the realities of gray-market peptide consumption.